R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Senior Director, Corporate Affairs - Communications and Policy Advocacy

PR & CommunicationsUpdated on Nov 13
Full-timeRemote in SpainNo salary listed

About the Job

Requirements

  • A degree in Law, Communications, Political Science, Public Health, Life Sciences, or a related field is required.
  • At least 10 years of experience in Communications and Public Affairs in oncology is required.
  • Strong ability to develop and deliver impactful Communications and Public Affairs campaigns is required.
  • Strong interpersonal, verbal, and written communication skills, including storytelling and translating policy for lay audiences, are required.
  • Experience managing complex stakeholder environments and partnerships is required.
  • Strong digital communications skills and experience running campaigns and stakeholder engagement across web, social, and other digital channels are required.
  • Hands-on fluency with generative AI tools for communications workflows, including drafting, monitoring, and sentiment analysis, and understanding responsible use, disclosure, and governance in a regulated industry are required.
  • A deep understanding of the European healthcare policy and oncology landscape is required.
  • A proven track record of engaging patient organizations, industry associations, and policymakers to deliver tangible policy and access outcomes is required.
  • Experience launching new oncology medicines and shaping policy to enable faster patient access is required.
  • Familiarity with reimbursement, health technology assessment processes, and access barriers in oncology is required.
  • Approximately 50% travel is required.

Responsibilities

  • Act as the spokesperson for Spain and Portugal, directing enquiries to internal experts as needed.
  • Drive proactive media content and strategy around trial results, regulatory milestones, and major oncology congresses, including ASCO and ESMO.
  • Build and maintain trusted relationships with top-tier and trade media in Spain and Portugal, ensuring accurate representation of company positions and achievements.
  • Monitor media coverage and sentiment, flagging emerging narratives before they require a crisis response.
  • Ensure consistent messaging across earned, owned, and shared channels, and align spokesperson strategy and media plans with global priorities.
  • Own the country-level corporate reputation strategy for Spain and Portugal, ensuring consistency with the global corporate narrative and brand.
  • Monitor reputation indicators and stakeholder sentiment, providing leadership early warning of emerging risks and opportunities.
  • Lead local crisis and issues management to protect and enhance the company’s reputation during sensitive events.
  • Build executive visibility and thought leadership within the local business, healthcare, and policy community, positioning leaders as trusted voices on oncology innovation.
  • Partner with the local Value, Market Access and Pricing team on corporate public affairs activities, including engagement with government and stakeholder institutions in Spain and Portugal on broader company issues.
  • Map and monitor the evolving policy environment in Spain and Portugal, including government, institutions, and regulatory bodies, and flag risks and opportunities to the business.
  • Partner with GMs, HR, and corporate functions to build a culture of transparency and pride in the company’s oncology impact.
  • Design engagement strategies that build commitment and translate strategy into clear priorities employees can act on.
  • Align internal messaging with external priorities, cascading Spain and Portugal policy and access milestones through engaging channels.
  • Lead oncology communications strategy in Spain and Portugal across disease awareness, launch, and lifecycle, including congress activity that translates clinical data for HCP and media audiences where and how permitted under local regulatory requirements.
  • Create disease-awareness content for patients and caregivers, and partner with Medical Affairs to translate clinical data into HCP-facing communications.
  • Ensure communications comply with European promotional codes (EFPIA) and local regulations, maintaining a clear promotional/non-promotional distinction and ethical standards.
  • Build team fluency in AI-enabled tools for audience insight, message drafting, and real-time measurement, and set standards for responsible, compliant use.
  • Develop best-practice toolkits, guidance, and training to build local advocacy and policy capacity, including AI and digital literacy.
  • Treat digital and AI-enabled engagement as core to contemporary corporate affairs and communications.
  • Foster cross-country learning and alignment on policy initiatives and emerging tools and practices.
  • Partner with regional and global teams to align Spain and Portugal communications with the global narrative, contributing policy insights, advocacy trends, and oncology milestones.

Desired Qualifications

  • A comprehensive understanding of the Spanish and Portuguese healthcare systems, reimbursement landscape, regulatory frameworks, and policy-making processes is advantageous.
  • A proven track record of successfully influencing healthcare policy and stakeholder perspectives in competitive markets is advantageous.
  • Strong strategic and analytical skills, with the ability to translate vision into actionable plans and navigate complex healthcare policy challenges, are advantageous.
  • Successful experience in cross-functional collaboration within matrix organizations and fast-paced entrepreneurial environments is advantageous.
  • Fluency in English, German, French, and/or Portuguese is advantageous.
  • Proficiency with MS Office and common business applications is advantageous.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs